foxo1

FOXO1 (Forkhead Box Protein O1)

FOXO1 is a Forkhead-family transcription factor and the principal downstream effector of insulin/AKT signaling in liver, β-cells, and skeletal muscle. When insulin is low (fasting), FOXO1 resides in the nucleus and drives gluconeogenic gene expression. When insulin is high, AKT-mediated phosphorylation at three conserved sites sequesters FOXO1 in the cytoplasm, suppressing hepatic glucose output. This nucleus/cytoplasm shuttle is the canonical “fasting metabolic switch.” FOXO1 is less directly tied to organismal longevity than its paralog foxo3, but is central to the deregulated-nutrient-sensing hallmark via its command over hepatic glucose homeostasis in aging and insulin resistance.

Identity

• UniProt: Q12778 (FOXO1_HUMAN; reviewed Swiss-Prot)
• NCBI Gene: 2308
• HGNC symbol: FOXO1 (previously FKHR — Forkhead In Rhabdomyosarcoma)
• Mouse ortholog: Foxo1 (one-to-one ortholog)
• Length: 655 amino acids (canonical human isoform)
• Historical alias: FKHR derived from the chromosomal translocation in alveolar rhabdomyosarcoma that first identified the locus ¹

Domain organization

Region	Residues (approx.)	Function
N-terminal regulatory domain	1–158	Contains AKT phospho-site Thr24; 14-3-3 docking
Forkhead (winged-helix) DNA-binding domain	159–235	Sequence-specific DNA binding to TGTTTAC motif; contains Ser256
Nuclear export sequence (NES)	~250–269	CRM1-dependent cytoplasmic export after phosphorylation
C-terminal transactivation domain	~456–655	Contains Ser319 AKT site; transcriptional activation; target of SIRT1 deacetylation at Lys245

Domain positions are approximate; verify against current UniProt feature annotations for exact residue numbers. unsourced — precise residue boundaries should be cross-checked against UniProt Q12778 feature table.

AKT phosphorylation and cytoplasmic sequestration

AKT phosphorylates FOXO1 at three conserved serine/threonine residues ²³:

Site	Kinase	Consequence
Thr24	AKT1/PKB	14-3-3 protein binding; one of two required docking sites
Ser256	AKT1/PKB	14-3-3 protein binding; second required docking site; overlaps NLS basic domain, disrupting nuclear import
Ser319	AKT1/PKB	Promotes cytoplasmic retention via nuclear export; does NOT contribute to 14-3-3 binding (analogous to FOXO3 Ser315, which binds 14-3-3 at wild-type levels when mutated alone)

14-3-3 binding requires phospho-Thr24 AND phospho-Ser256: by analogy with the directly demonstrated FOXO3 (FKHRL1) result in Brunet 1999 (where T32A+S253A double mutant abolishes 14-3-3 binding, S315A does not affect it), Thr24+Ser256 are the 14-3-3 docking sites in FOXO1; Ser319 drives a distinct nuclear-export mechanism ². For FOXO1 directly, Nakae 1999 establishes Ser256 (rat Ser253) as the primary insulin-responsive phosphorylation site and gatekeeper for PI3K-dependent nuclear exclusion ³. Dephosphorylation by pp2a (protein phosphatase 2A) or conditions of low insulin/PI3K activity (e.g., fasting, PTEN re-expression) allow nuclear re-import ³.

These three sites are conserved across FOXO paralogs: analogous to FOXO3 Thr32/Ser253/Ser315, FOXO4 Thr28/Ser193/Ser258.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes
Replicated in humans?	yes — insulin acutely suppresses hepatic glucose output via this mechanism in humans; AKT→FOXO1 arm confirmed in human hepatocytes

SIRT1 deacetylation — activation in fasting

Under fasting or oxidative stress conditions, SIRT1 deacetylates FOXO1 at Lys245 and Lys248 (within the forkhead domain), increasing FOXO1 transcriptional activity toward stress-resistance and metabolic targets. This provides a second, AKT-independent activation axis: caloric restriction → elevated NAD+ → SIRT1 active → FOXO1 deacetylated → target gene induction needs-replication (mechanism well-supported in cell lines; physiological flux less precisely quantified in vivo).

Transcriptional targets

Nuclear FOXO1 drives a broad transcriptional program. Key targets organized by context:

Hepatic gluconeogenesis (dominant aging-relevant context)

Gene	Product	Function
G6PC	Glucose-6-phosphatase (catalytic)	Terminal step of gluconeogenesis and glycogenolysis
PCK1	PEPCK-C (cytoplasmic)	Rate-limiting gluconeogenic enzyme; oxaloacetate → PEP
IGFBP1	IGF-binding protein 1	Sequesters circulating IGF-1

Liver-specific Foxo1 deletion (α1-antitrypsin-Cre × Foxo1^flox/flox, mixed C57BL/6 background) produces a 40% reduction in blood glucose at birth and 30% reduction in adult mice after 48 hr fast ⁴. Under hyperinsulinemic euglycemic clamp, hepatic glucose production is reduced >50% and both glycogenolysis and gluconeogenesis are each decreased ~50% ⁴. Fasting-induced G6pc and Pck1 expression are blunted 2- to 4-fold. Pgc1α cannot induce gluconeogenesis in Foxo1-deficient hepatocytes. These data establish FOXO1 as a non-redundant driver of both cAMP (glucagon-stimulated) and insulin-suppressed hepatic glucose production ⁴. needs-human-replication — mechanistic significance confirmed in mouse; human hepatic FOXO1 contribution to T2D pathophysiology is inferred from this and indirect pharmacology.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes — elevated hepatic glucose output in T2D patients consistent
Replicated in humans?	in-progress — hepatic FOXO1 activity inferred but not directly measured in vivo in humans

Pancreatic β-cell context

FOXO1 activity in β-cells promotes compensatory β-cell mass expansion under insulin-resistant conditions by sustaining Pdx1 expression ⁵. Constitutively active Foxo1^S253A targeted to β-cells suppresses Pdx1, reduces islet mass, and causes early-onset diabetes; conversely, Foxo1 haploinsufficiency rescues β-cell failure in Irs2-/- mice by increasing Pdx1 ⁵. Note: Foxa2 regulates hepatic Slc2a2 (Glut2) expression, NOT the G6PC/PCK1 gluconeogenic axis — Foxo1 and Foxa2 are parallel hepatic regulators of different target genes per Nakae 2002. Loss of FOXO1 in β-cells leads to impaired compensation and diabetes. This contrasts with the liver, where FOXO1 activity worsens glucose control. contradictory-evidence — FOXO1 is metabolically beneficial in β-cells but detrimental in liver; context-specific outputs.

Skeletal muscle atrophy

FOXO1 (and foxo3) is implicated in driving muscle atrophy by transactivating the ubiquitin ligases FBXO32 (Atrogin-1/MAFbx) and TRIM63 (MuRF1), which mediate myofibrillar protein degradation. This FOXO1 arm is inhibited downstream of akt activation by IGF-1/insulin — connecting nutrient sensing to sarcopenia. unsourced — the Atrogin-1/MuRF1 claim was attributed to ⁵ in the original draft but Nakae 2002 (Nat Genet) does not contain these targets; the FOXO-Atrogin-1/MuRF1 connection derives from Sandri et al. 2004 (Cell) and Stitt et al. 2004 (Mol Cell) — citation needs correction before this claim is load-bearing. needs-replication — direct FOXO1 ChIP evidence for Atrogin-1/MuRF1 promoter binding in human muscle is limited; most data from rodent models or C2C12 cells.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	partial — muscle atrophy and sarcopenia are conserved; degree of FOXO1 contribution vs FOXO3 in human muscle unclear
Replicated in humans?	no — human FOXO1-specific muscle atrophy evidence remains indirect

Cell cycle and stress responses

• p27/CDKN1B — FOXO1 activates CDKN1B → G1 cell-cycle arrest (shared mechanism with FOXO3)
• BIM (BCL2L11) — apoptosis initiator; less prominent for FOXO1 than FOXO3 in most contexts
• Catalase, MnSOD — antioxidant gene targets (stress resistance; SIRT1-dependent enhancement)

Discovery

FOXO1 was originally identified as the chromosomal breakpoint gene in the PAX3-FOXO1 fusion oncogene characteristic of alveolar rhabdomyosarcoma (ARMS), a pediatric soft-tissue sarcoma ¹. The translocation t(2;13)(q35;q14) fuses the N-terminal DNA-binding domain of PAX3 to the C-terminal transactivation domain of FOXO1 (then called FKHR), creating a constitutively active transcriptional activator. The “FKHR” name derives from this history. Its role in insulin signaling was established by Nakae et al. 1999 ³ (insulin-stimulated phosphorylation of FKHR/FOXO1 on Ser253/rat = Ser256/human, in SV40-transformed mouse hepatocytes) and Brunet et al. 1999 ² (AKT phosphorylation → 14-3-3 cytoplasmic sequestration → survival signaling — this paper characterizes FKHRL1/FOXO3a in CCL39 fibroblasts and neurons; FOXO1 sites are analogous by sequence homology).

Knockout phenotype

Foxo1-null mice (Foxo1−/−) die by embryonic day 10.5 from a defect in vascular remodeling (angiogenesis) ⁶. Hearts are still beating at E9.5 but embryos do not survive beyond E10.5. The primary defect is in embryonic angiogenesis (remodeling of the primary vascular plexus), not vasculogenesis — PECAM-1 staining at E9.5 shows primitive vasculature can form but fails to remodel; dorsal aorta, intersomitic vessels, and head vasculature are disorganized. Foxo1 is highly expressed in developing vascular endothelium (lacZ-based lineage tracing in Foxo1+/- embryos shows expression in dorsal aorta, posterior cardinal vein, intersomitic vessels, and extraembryonic vitelline/umbilical vessels). This embryonic lethality makes Foxo1 the most developmentally essential of the three somatic FOXO paralogs (Foxo3a- and Foxo4-null mice are viable and fertile) ⁶. Conditional liver-specific Foxo1 deletion is viable, hyperinsulinemic at baseline, and shows blunted fasting hyperglycemia ⁴. β-cell-specific Foxo1 deletion leads to impaired β-cell compensatory expansion under insulin-resistant conditions ⁵.

Role in aging and insulin resistance

The chronic FOXO1 activation problem in aging

In aged individuals with insulin resistance, hepatic FOXO1 is chronically active (inadequately suppressed by insulin signaling) despite hyperinsulinemia — a key paradox of T2D. AKT signaling becomes blunted, FOXO1 nuclear localization is incompletely suppressed, and G6PC/PCK1 transcription continues inappropriately, sustaining fasting hyperglycemia. This FOXO1-driven hepatic glucose overproduction is a central pathophysiological feature of type-2 diabetes in aging ⁴.

Contrast with FOXO3 in longevity

Unlike foxo3, whose gain-of-function (nuclear) variants in GWAS studies associate with exceptional human longevity, FOXO1 has no well-replicated longevity-associated human variant. FOXO3 is the dominant FOXO in hematopoietic and neuronal aging contexts; FOXO1 dominates hepatic and β-cell glucose metabolism. The paralog distinction matters: interventions that globally activate FOXO (e.g., PTEN overexpression, PI3K inhibition) affect both, with metabolic trade-offs. needs-human-replication — direct human longevity genetics for FOXO1 are not established.

FOXO1 as a therapeutic target in T2D

Selective FOXO1 inhibition in liver has been proposed as a T2D therapeutic strategy (suppress hepatic glucose output). Small-molecule FOXO1 inhibitors (e.g., AS1842856) reduce fasting glucose in rodent models. No FOXO1-targeting drug has advanced to Phase 2 clinical trials as of 2026. long-term-unknown — safety of chronic FOXO1 inhibition (β-cell compensation impairment, immune function, atrophy risk) is unresolved.

Pathway membership

• insulin-igf1 — canonical downstream effector (INSR → IRS1/2 → PI3K → AKT → FOXO1)
• pi3k-akt-pathway — direct AKT substrate; FOXO1 phospho-status reports on pathway activity
• gluconeogenesis — transcriptional master regulator in hepatocytes (stub)
• muscle-atrophy-pathway — Atrogin-1/MuRF1 axis (stub)

Key interactors

• akt — primary kinase; Thr24/Ser256/Ser319 phosphorylation → cytoplasmic sequestration
• insr — upstream receptor; insulin signal propagates to FOXO1 via IRS1/2 → PI3K → PDK1 → AKT
• sirt1 — deacetylates Lys245/Lys248; activates FOXO1 target genes in fasting/CR
• 14-3-3 — cytoplasmic anchor protein; binds phospho-Thr24 AND phospho-Ser256 (both required; by analogy with demonstrated FOXO3 Thr32+Ser253 requirement in Brunet 1999) → retains FOXO1 in cytoplasm; Ser319 phosphorylation does not contribute to 14-3-3 binding
• pp2a — phosphatase; dephosphorylates FOXO1 → nuclear re-import
• pax3 — fusion partner in alveolar rhabdomyosarcoma PAX3-FOXO1 oncogene (cancer context only)

Limitations and gaps

• #gap/needs-human-replication — Most hepatic gluconeogenesis mechanism data from mouse; direct human hepatic FOXO1 ChIP or nuclear localization measurements are limited.
• #gap/needs-human-replication — Muscle atrophy via FOXO1 well-established in rodent; human FOXO1-specific (vs FOXO3-specific) contribution to sarcopenia not resolved.
• #gap/needs-replication — SIRT1-mediated FOXO1 deacetylation flux in vivo quantitatively unconstrained; most data from overexpression systems.
• #gap/long-term-unknown — Consequences of chronic pharmacological FOXO1 inhibition (β-cell and immune effects) not characterized in aging-relevant long-term models.
• #gap/unsourced — Precise forkhead domain residue boundaries (Ser256 within vs. adjacent to domain) need cross-check against UniProt Q12778 feature table.
• The Foxo1-/- embryonic lethal citation gap is now resolved: Hosaka T et al. 2004 (PNAS 10.1073/pnas.0400093101) confirmed as the primary source; see ⁶.
• #gap/unsourced — Muscle atrophy via Atrogin-1/MuRF1 claim needs recitation: correct primary sources are Sandri et al. 2004 (Cell 117:399) and Stitt et al. 2004 (Mol Cell 14:395), not Nakae 2002.
• The distinction between FOXO1 vs FOXO3 vs FOXO4 target-gene specificity in overlapping tissues (especially muscle) is incompletely resolved in the primary literature.

Footnotes

Footnotes

1. doi:10.1038/ng1193-230 · Galili N et al. 1993 · in-vivo (human tumor genetics) · Nature Genetics · Fusion of PAX3 to FKHR forkhead domain in alveolar rhabdomyosarcoma (t(2;13)(q35;q14)); first identification of the FKHR/FOXO1 locus · closed-access paper; PDF path in archive ((stale local path) not accessible in this environment; claim consistent with archive title and widely corroborated ↩ ↩²

2. doi:10.1016/s0092-8674(00)80595-4 · Brunet A et al. 1999 · in-vitro (CCL39 fibroblasts, 293T cells, cerebellar granule neurons) · Cell 96:857-868 · AKT phosphorylates FKHRL1 (FOXO3a, NOT FOXO1) at Thr32/Ser253/Ser315; 14-3-3 binding requires phospho-Thr32 AND phospho-Ser253 (T32A+S253A double mutant abolishes 14-3-3 binding; S315A alone does not reduce it); Ser315 drives a distinct nuclear-export/mobility-shift mechanism independent of 14-3-3; seminal mechanistic paper establishing AKT-FOXO paradigm — sites transposed to FOXO1 analogs (Thr24/Ser256/Ser319) by sequence homology · local PDF available ↩ ↩² ↩³

3. doi:10.1074/jbc.274.23.15982 · Nakae J et al. 1999 · in-vitro (SV40-transformed mouse hepatocytes) · JBC 274:15982-15985 · Insulin stimulates phosphorylation of FKHR/FOXO1 directly in hepatocytes via PI3K/wortmannin-sensitive pathway; Ser253 (rat numbering; = Ser256 human) is the primary gatekeeper site — S253A abolishes insulin-induced phosphorylation; T24A and S316A (rat; = Ser319 human) reduce phosphorylation ~30% but do not abolish it; all three single mutants inhibit the insulin-induced mobility shift · local PDF available ↩ ↩² ↩³ ↩⁴

4. doi:10.1016/j.cmet.2007.08.006 · Matsumoto M et al. 2007 · in-vivo (liver-specific Foxo1 KO: α1-antitrypsin-Cre × Foxo1^flox/flox, mixed background) · Cell Metabolism 6:208-216 · Liver-specific Foxo1 deletion produces 40% blood glucose reduction at birth and 30% reduction after 48 hr fast in adults; hepatic glucose production reduced >50% under clamp; glycogenolysis and gluconeogenesis each reduced ~50%; fasting G6pc and Pck1 mRNA blunted 2- to 4-fold; Pgc1α cannot induce gluconeogenesis in Foxo1-deficient hepatocytes; Foxo1 required for both cAMP (glucagon) and insulin-regulated HGP — establishes FOXO1 as non-redundant shared regulator of both hormonal axes · n=6-13/group · local PDF available ↩ ↩² ↩³ ↩⁴ ↩⁵

5. doi:10.1038/ng890 · Nakae J et al. 2002 · in-vivo (Insr+/- Foxo1+/- double heterozygotes; Foxo1^S253A gain-of-function transgenics in liver and β-cells) · Nature Genetics 32:245-253 · Foxo1 haploinsufficiency rescues insulin resistance and reduces G6pc (~75% lower) and Pck1 expression in Insr+/- mice; constitutively active Foxo1^S253A in β-cells suppresses Pdx1 → impaired compensatory β-cell expansion → diabetes; Foxa2 is shown to regulate Slc2a2 (Glut2), NOT G6pc/Pck1 (those are Foxo1 targets); Atrogin-1/MuRF1 are NOT mentioned in this paper · n=8-15/group · local PDF available ↩ ↩² ↩³ ↩⁴

6. doi:10.1073/pnas.0400093101 · Hosaka T et al. 2004 · in-vivo (Foxo1-/- mice, C57BL/6 background) · PNAS 101:2975-2980 · Foxo1-null embryos die by E10.5; hearts beating at E9.5 but none survive beyond E10.5; primary defect is embryonic angiogenesis (remodeling of primary vascular plexus), not vasculogenesis — PECAM-1 staining shows primitive vessels form at E9.5 but fail to remodel; dorsal aorta thin/disorganized, intersomitic vessels irregular, head vasculature lacks proper internal carotid artery branching; lacZ lineage tracing confirms Foxo1 expression in vascular endothelium; Foxo3a- and Foxo4-null mice viable and fertile; ref 18 in paper = Nakae 2002 (Nat Genet), which first reported Foxo1-/- lethality · local PDF available ↩ ↩² ↩³